Paradigm Biopharmaceuticals Limited (ASX: PAR) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Paradigm Biopharmaceuticals Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Paradigm Biopharmaceuticals Limited (ASX: PAR)
Latest News
Capital Raising
Up 90% in 2 weeks, here's why the Paradigm share price has been halted
Share Gainers
Why Appen, Imugene, OZ Minerals, and Paradigm shares are charging higher
Healthcare Shares
Why is the Paradigm Biopharmaceuticals share price up 12% on Monday?
Healthcare Shares
Why is the Paradigm share price surging 7% today?
Index investing
ASX 200 healthcare shares provided some pain relief today. Here's why
Healthcare Shares
Why is the Paradigm share price rocketing 20% higher today?
Broker Notes
Leading brokers name 3 ASX shares to buy today
Healthcare Shares
Why is the Paradigm share price surging 6% today?
Healthcare Shares
Why is the Paradigm share price surging 5% today?
Healthcare Shares
The Paradigm share price is rocketing 22% today. Here's why
Share Gainers
Why Iress, Krakatoa Resources, Paradigm, and SE Advanced Materials are pushing higher
Broker Notes
Top brokers name 3 ASX shares to sell today
Frequently Asked Questions
-
No, Paradigm does not pay shareholder dividends at this time.
-
Paradigm Biopharmaceuticals Limited listed on the ASX on 19 August 2015.
PAR ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Paradigm Biopharmaceuticals Limited
Paradigm Biopharmaceuticals Ltd (ASX: PAR) is a late-stage drug development company researching drug repurposing. The company seeks to identify and transform existing molecules to develop effective treatments for conditions with limited treatment options. Currently, more than 30% of therapies approved or launched globally represent drugs approved for new indications, reformulations, or new combinations of existing drugs.
Paradigm's current commercial prospect is injectable pentosan polysulfate sodium (PPS, or brand name Zilosul®) in the treatment of osteoarthritis. PPS is FDA-approved and has a track record of treating inflammation including bladder condition cystitis and is used in the EU for preventing deep vein thrombosis. Paradigm has advanced to Phase 3 trial stage investigating PPS for osteoarthritis treatment. The company is based in Melbourne with offices in the US and Europe.
